BeOne Medicines Ltd. (ONC): who owns it and who trades it
As of Nov 16, 2026, ONC insiders reported 205 open-market sales worth $386M and no purchases in the last 12 months, with 97% of the sale value made under pre-set 10b5-1 plans. The largest seller was John Oyler (CEO), with $328M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling BeOne Medicines
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ONC
279 funds and institutions reported ONC shares worth $9.9B at the end of Q2 2026, about 2% of the company. The largest holder is Baker Bros. Advisors LP with 0.6%.
Funds and institutions (13F) 2%Everyone else 98%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 8.80M | 0.61% | $2.5B | No change |
| Primecap Management Co | 5.01M | 0.35% | $1.4B | +1% |
| Capital International Investors | 4.21M | 0.29% | $1.2B | +1% |
| FMR LLC (Fidelity) | 2.48M | 0.17% | $706M | -33% |
| Capital World Investors | 2.25M | 0.16% | $641M | +39% |
| Citadel Advisors LLC | 1.43M | 0.10% | $406M | +38% |
| Temasek Holdings (Private) Ltd | 845,729 | 0.06% | $241M | -2% |
| T. Rowe Price Associates | 758,752 | 0.05% | $216M | +41% |
| BlackRock, Inc. | 694,618 | 0.05% | $198M | +6% |
| Millennium Management LLC | 543,323 | 0.04% | $155M | +165% |
| Morgan Stanley | 497,437 | 0.03% | $142M | +7% |
| Siren, L.L.C. | 465,000 | 0.03% | $133M | No change |
| Bank of America Corp | 439,336 | 0.03% | $125M | +8% |
| Baird Financial Group, Inc. | 368,978 | 0.03% | $105M | +6% |
| Man Group plc | 307,463 | 0.02% | $87.6M | +27% |
| Capital International, Inc. | 305,477 | 0.02% | $87.1M | +1% |
| Candriam S.C.A. | 289,735 | 0.02% | $82.5M | +12% |
| Two Sigma Investments, LP | 286,552 | 0.02% | $81.7M | +754% |
| UBS Group AG | 258,589 | 0.02% | $73.7M | -38% |
| Arrowstreet Capital, Limited Partnership | 249,758 | 0.02% | $71.2M | +126% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ONC insiders reported $0 of open-market purchases and $386M of sales. 97% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 6, 2026 | Titus B. Ball | Principal Accounting Off | Sale | 1,533 | $405.55 | $622K | Form 4 |
| Nov 6, 2026 | Titus B. Ball | Principal Accounting Off | Sale | 26 | $406.34 | $10.6K | Form 4 |
| Nov 5, 2026 | Chan Henry Lee | Vice president | Sale plan | 660 | $400.00 | $264K | Form 4 |
| Nov 5, 2026 | Chan Henry Lee | Vice president | Sale plan | 455 | $402.00 | $183K | Form 4 |
| Oct 27, 2026 | Xiaodong Wang | Director | Sale plan | 880 | $355.56 | $313K | Form 4 |
| Oct 27, 2026 | Xiaodong Wang | Director | Sale plan | 1,440 | $355.62 | $512K | Form 4 |
| Oct 27, 2026 | Xiaodong Wang | Director | Sale plan | 1,239 | $357.54 | $443K | Form 4 |
| Oct 27, 2026 | Xiaodong Wang | Director | Sale plan | 1,681 | $358.75 | $603K | Form 4 |
| Oct 27, 2026 | Xiaodong Wang | Director | Sale plan | 1,280 | $359.72 | $460K | Form 4 |
| Oct 27, 2026 | Xiaodong Wang | Director | Sale plan | 320 | $360.64 | $115K | Form 4 |
| Oct 27, 2026 | Xiaodong Wang | Director | Sale plan | 2,331 | $362.35 | $845K | Form 4 |
| Oct 27, 2026 | Xiaodong Wang | Director | Sale plan | 8,148 | $363.24 | $3M | Form 4 |
| Oct 27, 2026 | Xiaodong Wang | Director | Sale plan | 2,841 | $363.95 | $1M | Form 4 |
| Oct 27, 2026 | Xiaodong Wang | Director | Sale plan | 3,965 | $365.43 | $1.4M | Form 4 |
| Oct 27, 2026 | Xiaodong Wang | Director | Sale plan | 6,903 | $366.22 | $2.5M | Form 4 |
| Oct 13, 2026 | Xiaodong Wang | Director | Sale plan | 7,167 | $349.56 | $2.5M | Form 4 |
| Oct 13, 2026 | Xiaodong Wang | Director | Sale plan | 10,361 | $350.47 | $3.6M | Form 4 |
| Oct 13, 2026 | Xiaodong Wang | Director | Sale plan | 5,681 | $351.40 | $2M | Form 4 |
| Oct 13, 2026 | Xiaodong Wang | Director | Sale plan | 6,558 | $352.57 | $2.3M | Form 4 |
| Oct 13, 2026 | Xiaodong Wang | Director | Sale plan | 1,260 | $353.24 | $445K | Form 4 |
| Sep 30, 2026 | Chan Henry Lee | Vice president | Sale plan | 1,115 | $375.00 | $418K | Form 4 |
| Sep 28, 2026 | Xiaodong Wang | Director | Sale plan | 160 | $356.97 | $57.1K | Form 4 |
| Sep 28, 2026 | Xiaodong Wang | Director | Sale plan | 120 | $358.71 | $43K | Form 4 |
| Sep 28, 2026 | Xiaodong Wang | Director | Sale plan | 40 | $359.16 | $14.4K | Form 4 |
| Sep 28, 2026 | Xiaodong Wang | Director | Sale plan | 2,241 | $361.05 | $809K | Form 4 |
| Sep 28, 2026 | Xiaodong Wang | Director | Sale plan | 738 | $367.23 | $271K | Form 4 |
| Sep 28, 2026 | Xiaodong Wang | Director | Sale plan | 3,499 | $363.10 | $1.3M | Form 4 |
| Sep 28, 2026 | Xiaodong Wang | Director | Sale plan | 3,419 | $364.07 | $1.2M | Form 4 |
| Sep 28, 2026 | Xiaodong Wang | Director | Sale plan | 2,047 | $365.85 | $749K | Form 4 |
| Sep 28, 2026 | Xiaodong Wang | Director | Sale plan | 14,525 | $366.58 | $5.3M | Form 4 |
| Sep 28, 2026 | Xiaodong Wang | Director | Sale plan | 4,239 | $362.17 | $1.5M | Form 4 |
| Sep 8, 2026 | Xiaodong Wang | Director | Sale plan | 10,688 | $349.28 | $3.7M | Form 4 |
| Sep 8, 2026 | Xiaodong Wang | Director | Sale plan | 7,492 | $348.31 | $2.6M | Form 4 |
| Sep 8, 2026 | Xiaodong Wang | Director | Sale plan | 1,181 | $345.38 | $408K | Form 4 |
| Sep 8, 2026 | Xiaodong Wang | Director | Sale plan | 6,569 | $350.27 | $2.3M | Form 4 |
| Sep 8, 2026 | Xiaodong Wang | Director | Sale plan | 1,721 | $348.01 | $599K | Form 4 |
| Sep 8, 2026 | Xiaodong Wang | Director | Sale plan | 1,517 | $347.39 | $527K | Form 4 |
| Sep 8, 2026 | Xiaodong Wang | Director | Sale plan | 2,841 | $346.16 | $983K | Form 4 |
| Sep 8, 2026 | Xiaodong Wang | Director | Sale plan | 6,278 | $351.25 | $2.2M | Form 4 |
| Sep 1, 2026 | Titus B. Ball | Principal Accounting Off | Sale | 132 | $355.86 | $47K | Form 4 |
| Aug 25, 2026 | Xiaobin Wu | President | Sale plan | 280 | $380.00 | $106K | Form 4 |
| Aug 12, 2026 | John Oyler | CEO | Sale plan | 14,102 | $359.12 | $5.1M | Form 4 |
| Aug 12, 2026 | John Oyler | CEO | Sale plan | 1,980 | $354.71 | $702K | Form 4 |
| Aug 12, 2026 | John Oyler | CEO | Sale plan | 2,515 | $356.43 | $896K | Form 4 |
| Aug 12, 2026 | John Oyler | CEO | Sale plan | 15,396 | $357.63 | $5.5M | Form 4 |
| Aug 12, 2026 | John Oyler | CEO | Sale plan | 20,899 | $358.41 | $7.5M | Form 4 |
| Aug 11, 2026 | Chan Henry Lee | Vice president | Sale plan | 2,666 | $360.00 | $960K | Form 4 |
| Aug 11, 2026 | John Oyler | CEO | Sale plan | 13,695 | $359.32 | $4.9M | Form 4 |
| Aug 11, 2026 | John Oyler | CEO | Sale plan | 8,081 | $360.33 | $2.9M | Form 4 |
| Aug 11, 2026 | John Oyler | CEO | Sale plan | 14,569 | $361.47 | $5.3M | Form 4 |
| Aug 11, 2026 | John Oyler | CEO | Sale plan | 11,568 | $362.34 | $4.2M | Form 4 |
| Aug 11, 2026 | John Oyler | CEO | Sale plan | 13,403 | $363.45 | $4.9M | Form 4 |
| Aug 11, 2026 | John Oyler | CEO | Sale plan | 5,211 | $364.31 | $1.9M | Form 4 |
| Aug 11, 2026 | John Oyler | CEO | Sale plan | 3,176 | $365.26 | $1.2M | Form 4 |
| Aug 11, 2026 | John Oyler | CEO | Sale plan | 1,200 | $366.31 | $440K | Form 4 |
| Aug 11, 2026 | John Oyler | CEO | Sale plan | 4 | $367.00 | $1.5K | Form 4 |
| Aug 10, 2026 | John Oyler | CEO | Sale plan | 67 | $350.00 | $23.4K | Form 4 |
| Aug 10, 2026 | John Oyler | CEO | Sale plan | 3,673 | $353.32 | $1.3M | Form 4 |
| Aug 10, 2026 | John Oyler | CEO | Sale plan | 6,717 | $354.78 | $2.4M | Form 4 |
| Aug 10, 2026 | John Oyler | CEO | Sale plan | 3,476 | $355.66 | $1.2M | Form 4 |
| Aug 10, 2026 | John Oyler | CEO | Sale plan | 12,418 | $356.62 | $4.4M | Form 4 |
| Aug 10, 2026 | John Oyler | CEO | Sale plan | 15,869 | $357.67 | $5.7M | Form 4 |
| Aug 10, 2026 | John Oyler | CEO | Sale plan | 45,044 | $358.70 | $16.2M | Form 4 |
| Aug 10, 2026 | John Oyler | CEO | Sale plan | 21,254 | $359.50 | $7.6M | Form 4 |
| Aug 10, 2026 | John Oyler | CEO | Sale plan | 3,680 | $360.63 | $1.3M | Form 4 |
| Aug 10, 2026 | John Oyler | CEO | Sale plan | 2,813 | $351.80 | $990K | Form 4 |
| Aug 3, 2026 | Aaron Rosenberg | CFO | Sale | 1,157 | $312.72 | $362K | Form 4 |
| Jul 30, 2026 | Chan Henry Lee | Vice president | Sale | 1,044 | $323.69 | $338K | Form 4 |
| Jul 22, 2026 | Chan Henry Lee | Vice president | Sale plan | 1,669 | $325.00 | $542K | Form 4 |
| Jul 21, 2026 | John Oyler | CEO | Sale plan | 15,379 | $316.26 | $4.9M | Form 4 |
| Jul 21, 2026 | John Oyler | CEO | Sale plan | 20,029 | $316.91 | $6.3M | Form 4 |
| Jul 21, 2026 | John Oyler | CEO | Sale plan | 7,842 | $318.41 | $2.5M | Form 4 |
| Jul 21, 2026 | John Oyler | CEO | Sale plan | 15,807 | $319.29 | $5M | Form 4 |
| Jul 21, 2026 | John Oyler | CEO | Sale plan | 2,340 | $320.06 | $749K | Form 4 |
| Jul 20, 2026 | John Oyler | CEO | Sale plan | 15,499 | $312.29 | $4.8M | Form 4 |
| Jul 20, 2026 | John Oyler | CEO | Sale plan | 14,326 | $312.96 | $4.5M | Form 4 |
| Jul 20, 2026 | John Oyler | CEO | Sale plan | 1,850 | $313.91 | $581K | Form 4 |
| Jul 20, 2026 | John Oyler | CEO | Sale plan | 1,512 | $315.26 | $477K | Form 4 |
| Jul 20, 2026 | John Oyler | CEO | Sale plan | 523 | $316.14 | $165K | Form 4 |
| Jul 20, 2026 | John Oyler | CEO | Sale plan | 280 | $318.30 | $89.1K | Form 4 |
| Jul 20, 2026 | John Oyler | CEO | Sale plan | 5,146 | $310.08 | $1.6M | Form 4 |
| Jul 20, 2026 | John Oyler | CEO | Sale plan | 2,907 | $311.80 | $906K | Form 4 |
| Jul 20, 2026 | John Oyler | CEO | Sale plan | 6,273 | $310.75 | $1.9M | Form 4 |
| Jul 17, 2026 | John Oyler | CEO | Sale plan | 1,440 | $305.20 | $439K | Form 4 |
| Jul 17, 2026 | John Oyler | CEO | Sale plan | 597 | $306.96 | $183K | Form 4 |
| Jul 17, 2026 | John Oyler | CEO | Sale plan | 680 | $309.05 | $210K | Form 4 |
| Jul 17, 2026 | John Oyler | CEO | Sale plan | 4,833 | $310.37 | $1.5M | Form 4 |
| Jul 17, 2026 | John Oyler | CEO | Sale plan | 35,829 | $312.17 | $11.2M | Form 4 |
| Jul 17, 2026 | John Oyler | CEO | Sale plan | 14,915 | $313.19 | $4.7M | Form 4 |
| Jul 17, 2026 | John Oyler | CEO | Sale plan | 740 | $314.32 | $233K | Form 4 |
| Jul 17, 2026 | John Oyler | CEO | Sale plan | 51 | $315.06 | $16.1K | Form 4 |
| Jul 17, 2026 | John Oyler | CEO | Sale plan | 5,543 | $311.42 | $1.7M | Form 4 |
| Jul 16, 2026 | John Oyler | CEO | Sale plan | 42,798 | $317.79 | $13.6M | Form 4 |
| Jul 16, 2026 | John Oyler | CEO | Sale plan | 32,224 | $316.82 | $10.2M | Form 4 |
| Jul 16, 2026 | John Oyler | CEO | Sale plan | 15,097 | $319.99 | $4.8M | Form 4 |
| Jul 16, 2026 | John Oyler | CEO | Sale plan | 20,505 | $321.00 | $6.6M | Form 4 |
| Jul 16, 2026 | John Oyler | CEO | Sale plan | 13,109 | $321.61 | $4.2M | Form 4 |
| Jul 16, 2026 | John Oyler | CEO | Sale plan | 1,560 | $322.71 | $503K | Form 4 |
| Jul 16, 2026 | John Oyler | CEO | Sale plan | 520 | $323.59 | $168K | Form 4 |
| Jul 16, 2026 | John Oyler | CEO | Sale plan | 233 | $311.98 | $72.7K | Form 4 |
Latest 100 of 205 trades in the last 12 months.
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| John Oyler | Chief Executive Officer, Director | – | $328M | Aug 12, 2026 |
| Xiaodong Wang | Director | – | $46.8M | Oct 27, 2026 |
| Chan Henry Lee | SVP, General Counsel | – | $4.7M | Nov 5, 2026 |
| Xiaobin Wu | President and COO | – | $2.9M | Aug 25, 2026 |
| Lai Wang | President, Global Head of R&D | – | $1.2M | Jun 23, 2026 |
| Corazon (Corsee) D. Sanders | Director | – | $961K | May 22, 2026 |
| Titus B. Ball | Principal Accounting Officer | – | $760K | Nov 6, 2026 |
| Aaron Rosenberg | Chief Financial Officer | – | $524K | Aug 3, 2026 |
| Baker Bros. Advisors Lp | Director | – | $131K | May 22, 2026 |
| Margaret Dugan | Director | – | $65.6K | May 22, 2026 |
| Alessandro Riva | Director | – | $65.6K | May 22, 2026 |
| Qingqing Yi | Director | – | $65.6K | Jun 1, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ONC short interest
Low short interest. 0.1% of ONC shares are sold short: about 1 share in 927. Over the last 12 reports the number of shares short went up 53%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 1.60M ONC shares were sold short, 0.1% of the shares outstanding, down 10.6% from the report before. At the average daily volume of 366,722 shares, buying them all back would take about 4.4 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 1.60M | 0.11% | -11% | 366,722 | 4.4 |
| Oct 15, 2026 | 1.79M | 0.12% | -7% | 367,896 | 4.9 |
| Sep 30, 2026 | 1.93M | 0.13% | +13% | 389,451 | 5.0 |
| Sep 15, 2026 | 1.71M | 0.12% | +20% | 378,473 | 4.5 |
| Aug 31, 2026 | 1.42M | 0.10% | +11% | 341,689 | 4.2 |
| Aug 14, 2026 | 1.28M | 0.09% | +45% | 455,798 | 2.8 |
| Jul 31, 2026 | 880,627 | 0.06% | -5% | 372,520 | 2.4 |
| Jul 15, 2026 | 926,986 | 0.06% | +17% | 352,696 | 2.6 |
| Jun 30, 2026 | 791,577 | 0.05% | -12% | 296,408 | 2.7 |
| Jun 15, 2026 | 902,392 | 0.06% | -17% | 311,622 | 2.9 |
| May 29, 2026 | 1.09M | 0.08% | +4% | 222,577 | 4.9 |
| May 15, 2026 | 1.05M | 0.07% | -6% | 252,348 | 4.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
BeOne Medicines company events
BeOne Medicines filed 12 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Aug 26, 2026ResultsReleased financial results. Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jun 26, 2026AnnouncementAs previously disclosed in the Quarterly Report on Form 10-Q filed by BeOne Medicines Ltd. with the Securities and Exchange Commission on May 6, 2026, the Company is subject to ongoing tax audits that may result in liabilities which could be materially different from current estimates due to the… Filing
- Jun 11, 2026LeadershipAs previously disclosed in the definitive proxy statement for the 2026 Annual General Meeting of Shareholders of BeOne Medicines Ltd. filed with the U.S. Securities and Exchange Commission on April 28, 2026, Mr. Michael Goller, Mr. Ranjeev Krishana, Dr. Corazon (Corsee) D. Sanders and Mr. Qingqing… Filing
- May 15, 2026AnnouncementBeOne Medicines Ltd. announced that BEQALZI™ (sonrotoclax) has received accelerated approval from the U.S. Food and Drug Administration for the treatment of adult patients with relapsed or refractory mantle cell lymphoma, after at least two lines of systemic therapy, including a Bruton’s tyrosine… Filing
- May 6, 2026ResultsReleased financial results. Filing
- Apr 14, 2026ResultsReleased financial results. Filing
- Feb 26, 2026ResultsReleased financial results. Filing
- Dec 19, 2025AgreementEnded an important agreement. Filing
- Dec 18, 2025LeadershipBeOne Medicines Ltd. appointed Dr. Lai Wang to serve as President, Global Head of Research and Development of the Company. Filing
- Nov 19, 2025AgreementEntry into Facilities Agreement On November 13, 2025 (November 14, 2025 Hong Kong time), BeOne Medicines Ltd. entered into the Facilities Agreement, by and among (i) certain subsidiaries of the Company listed in the Facilities Agreement, as guarantors, (ii) The Hongkong and Shanghai Banking… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
BeOne Medicines financials
Famous investors that hold ONC
4 of the 50 well-known investors we track reported holding ONC in their latest 13F filing. The largest position is Ken Griffin's, worth $190M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 520,094 | $190M | 0.1% | -64% |
| Israel Englander · Millennium Management | Q3 2026 | 278,720 | $102M | 0.1% | -49% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 139,805 | $51.2M | 0.1% | +37% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 1,002 | $367K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named ONC in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 13, 2026 | OYLER JOHN | 13G/A | 3.6% |
| Nov 13, 2026 | OYLER JOHN | 13G/A | 3.6% |
Questions about BeOne Medicines Ltd. (ONC) stock
Who owns the most ONC stock?
The largest reported owner of BeOne Medicines Ltd. (ONC) is Baker Bros. Advisors LP, with 0.6% of the company. In total, 279 funds and institutions reported holding ONC at the end of Q2 2026, together about 2% of the shares. See the largest owners.
Are ONC insiders buying or selling?
In the last 12 months, ONC insiders reported no open-market purchases and 205 sales worth $386M. The latest trade was on Nov 6, 2026. See every trade.
What is the short interest in ONC?
As of Oct 30, 2026, 1.60M ONC shares were sold short, 0.1% of the shares outstanding, down 10.6% from the report before. At the average daily volume of 366,722 shares, buying them all back would take about 4.4 trading days (days to cover). See the history.
Which famous investors hold ONC?
4 of the 50 well-known investors we track reported ONC in their latest 13F filing, including Ken Griffin, Israel Englander, Jim Simons. The largest position is worth $190M. See all holders.
Executive pay
BeOne Medicines's chief executive was paid a total of $17.9M for the year ended Dec 31, 2025, down 14% from $20.8M the year before. In the last 12 months, BeOne Medicines's executives and directors bought no stock on the open market and sold $386M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.